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Introduction {#sec005}
============

The spirochetes of the *Treponema* genus consists of different species and subspecies causing syphilis, bejel, yaws and pinta infections. *Treponema pallidum* subspecies *pallidum* (TPA) is the causative pathogen of syphilis, a world-wide prevalent venereal disease. In 2017, there were 33,189 syphilis cases reported in 28 EU/EEA Member States giving an incidence rate of 7.1 cases per 100 000 population \[[@pone.0230288.ref001]\]. The increasing rates of syphilis cases is mainly driven by behavioral factors and testing strategies by focusing on the risk-group of men who have sex with men (MSM), who accounted for 96% of the 1,224 syphilis cases in the Netherlands in 2018 \[[@pone.0230288.ref002]\].

Bejel is caused by *T*. *pallidum* subsp. *endemicum* (TEN) and was, until recently, thought to be non-venereal \[[@pone.0230288.ref003]--[@pone.0230288.ref005]\]. Bejel shows similar clinical manifestations and is morphologically and serologically indistinguishable from TPA \[[@pone.0230288.ref006]\]. In 2016, a TEN isolate was identified in France \[[@pone.0230288.ref007]\]. A recently developed multilocus sequence typing (MLST) scheme \[[@pone.0230288.ref008]\] enables differentiation between treponemal subspecies as well as the distinction between the two major genetic clades within TPA, Nichols and SS14, and provides strain types within these clades. In 2018, this MLST method was used in Cuba \[[@pone.0230288.ref006]\] and Japan \[[@pone.0230288.ref009]\] to retrospectively investigate treponemal subspecies in samples of patients that were diagnosed with syphilis. Interestingly, both studies found cases of bejel, caused by TEN, which strongly suggested sexual transmission of this disease and showed bejel cases outside of the known endemic areas, Sahelian Africa and Saudi Arabia \[[@pone.0230288.ref004]\].

This study aimed to discover TEN strains causing bejel among syphilis cases from patients with Surinamese or Antillean ethnicity assuming possible importation of bejel from their country of origin. We hypothesized that if bejel was also misdiagnosed in Amsterdam, as was the case in Cuba among patients with syphilis \[[@pone.0230288.ref006]\], we would more likely find TEN in Dutch patients with a Surinamese or Antillean ethnicity, as these countries are geographically close to Cuba ([Fig 1](#pone.0230288.g001){ref-type="fig"}), than in patients with a Dutch ethnicity. Dutch patients were also included to investigate the presence of bejelin Amsterdam.

![Map showing geographical location of Cuba (red), the Dutch Antilles (green) and Surinam (blue).\
This map was constructed using [matchart.net](https://matchart.net).](pone.0230288.g001){#pone.0230288.g001}

In addition, molecular characterization data was used to increase the epidemiological knowledge of the strain types and investigate possible associations between allelic types, profiles and patient's clinical and demographical data.

Methods {#sec006}
=======

Sample selection and preparation {#sec007}
--------------------------------

Based on a positive *polA* PCR on genital ulcer swabs \[[@pone.0230288.ref010]\] 137 samples were retrospectively selected from patients with a Surinamese, Antillean or Dutch nationality visiting the STI clinic in Amsterdam between 2006 and 2018. Within this time frame all available samples from syphilis diagnosed Surinamese and Antillean patients were included in the study. For a more representative and equal spread of samples the number of Dutch samples were randomly selected per calendar year to match the number of samples from Antillean and Surinamese patients.

If the volume of the DNA isolate was insufficient, DNA from the original patient sample, which was stored at -20°C, was re-extracted using isopropanol precipitation method \[[@pone.0230288.ref011]\]. Demographic and clinical data was collected for all patients.

Defining clinical stages of syphilis {#sec008}
------------------------------------

The primary stage of syphilis is defined as an oro-, ano-genital ulcerative disease with a positive dark field microscopy and/or with a positive ulcer swab PCR result. Criteria for secondary syphilis are a rash with or without lymphadenopathy, or mucosal lesions such as condylomata lata, and an RPR ≥ 1:4. Ulcers may also occur in patients presenting with a rash with or without lymphadenopathy, or mucosal lesions. These patients are diagnosed with secondary syphilis. All samples from this study are ulcer swabs and were derived from both (primary and secondary) clinical syphilis stages.

Serological testing {#sec009}
-------------------

Serologically, until 2013 a *Treponema pallidum* particle agglutination (TPPA) assay was performed on all samples. After 2013, the enzyme immunoassay (EIA) for the detection of IgM antibodies to *Treponema pallidum* was introduced and used on all samples unless the patient had a syphilis infection before. In addition, quantitative rapid plasma reagin (RPR) flocculation test (RPR-Nosticon II; bioMérieux) was performed according to the specifications of the manufacturers.

Molecular typing method {#sec010}
-----------------------

Molecular characterization of the samples was performed using the recently developed MLST method by Grillová et al. 2018 \[[@pone.0230288.ref008]\]. This MLST method is based on the partial amplification and sequence analysis of three chromosomal loci; *tp0136*, *tp0548* and *tp0705*. Also both 23S rRNA genes were partly sequenced to check for the A2058G and A2059G mutations associated with macrolide resistance. The partial amplification and sequence analysis using Sanger sequencing was performed as described \[[@pone.0230288.ref008], [@pone.0230288.ref012]\]. Sequence analyses were performed using Bionumerics version 7.6.3 (Applied Maths, BioMérieux). All allelic variants and allelic profiles were added to the PubMLST BIGSdb database of TPA \[[@pone.0230288.ref013]\]. New allelic variants and profiles were given subsequent numbers adding to the TPA database. Typed isolates were uploaded when 2 or more allelic variants were identified.

Genetic clade and subspecies distinction {#sec011}
----------------------------------------

Clade determination (SS14-like or Nichols-like) was possible with the partly sequenced regions of *tp0136* and *tp0548*. Every new allelic variant was compared to both references in order to determine its genetic group. To visualize subspecies and genetic clades a phylogenetic tree of the concatenated sequences was generated with the bootstrapping maximum-likelihood algorithm and the Tamura-Nei method in MEGA6.06 \[[@pone.0230288.ref014]\].

Data analysis {#sec012}
-------------

Allelic profiles, demographic and clinical data were tested for possible associations with Fisher's Exact Tests and, where possible, Pearson's Chi-square Tests between patients with fully typable and not (fully) typable samples using IBM SPSS Statistics (version 21.0.0.2). A p\<0.05 was considered significant.

Ethical clearing {#sec013}
----------------

This study was reviewed, and the need for consent was waived by our Institutional Review Board, which is the Medical Ethical Committee of the Amsterdam University Medical Centers in the Netherlands. According to the Dutch Medical Research Act Involving Human Subjects on use of retrospective diagnostic material no additional ethical approval was required for this study (W19_113\#19.146). An opt-out system is used at the Public Health Service of Amsterdam to assure that if patients object to having their samples used for research that these are destroyed. Only anonymized patient data were used as provided by an independent datamanager. No samples from patients under the age of 18 years old were included.

Results {#sec014}
=======

Isolated DNA samples were available from 137 ulcer swabs and derived from 24 Antillean patients, 46 Surinamese patients and 67 Dutch patients. Patient characteristics were collected for all 137 patients and are shown in [Table 1](#pone.0230288.t001){ref-type="table"}. Dutch patients had a higher median age, 46 years with an interquartile range (IQR) of 38--51, compared to 37 years (IQR 29--45) in Surinamese and 35 years (IQR 31--41) in Antillean patients. Only 67% of the Surinamese patients were MSM based on their sexual behavior in the past 6 months. This is much lower compared to the 91% and 92% among the Dutch and Antillean patients. The HIV status among all ethnicities was similar with 40% HIV positive Dutch patients, 39% Surinamese and 46% Antillean.

10.1371/journal.pone.0230288.t001

###### Demographic and clinical characteristics of all 137 patients.

![](pone.0230288.t001){#pone.0230288.t001g}

  Clinical characteristics of patients   (n = 137)
  -------------------------------------- -------------
  **General**                            
   Ethnicity                             
    Antillean                            24
    Surinamese                           46
    Dutch                                67
   Median age (IQR)                      41 (34--48)
   Sex (%)                               
    Male                                 136 (99.3)
    Female                               1 (0.7)
   Sexual behavior (%)                   
    MSM                                  114 (83.2)
    MWMW                                 11 (8.0)
    MSW                                  11 (8.0)
    WSM                                  1 (0.7)
   HIV status (%)                        
    Positive                             56 (40.9)
    Negative                             75 (54.7)
    Unknown                              6 (4.4)
  **Serology**                           
   RPR (%)                               
    High (1:32 ≤)                        43 (31.4)
    Middle (1:4--1:16)                   42 (30.7)
    Low (1:1--1:2)                       26 (19.0)
    Negative                             24 (17.5)
    Unknown                              2 (1.5)
   TPPA/EIA (%)                          
    Positive                             102 (74.5)
    Negative                             4 (2.9)
    Not tested                           26 (18.9)
    Unknown                              5 (3.7)
  **Syphilis stage**                     
   Primary syphilis (%)                  108 (78.8)
   Secondary syphilis (%)                29 (21.2)

MSM, men who have sex with men; MSMW, men who have sex with men and women; MSW, men who have sex with women; WSM, women who have sex with men.

From the 137 DNA samples 103 (75%) were successfully amplified and analyzed for all typing loci. This resulted in 17 distinct allelic profiles ([Fig 2](#pone.0230288.g002){ref-type="fig"}). Of these samples, 85 (82.5%) were SS14-like and 18 (17.5%) Nichols-like strains. The most common allelic profile found was 1.3.1 occurring in 42/99 (42%) isolates. None of the samples in this study were TEN.

![An overview of allelic profiles colored by ethnicity.\
Molecular typing of 137 Treponema pallidum subspecies pallidum isolates from Amsterdam.](pone.0230288.g002){#pone.0230288.g002}

In addition, a total of 6 allelic variants were found for locus *tp0136*, 11 for *tp0548* and 5 for *tp0705*. Of these, 7 were new allelic variants, 2 for the *tp0136* locus (numbers 19 and 20) and 5 for the *tp0548* locus (numbers 43--47). In total, 10 new allelic profiles were found with new and known allelic variants giving rise to a total of 10 new ST (numbered 56--65, [Table 2](#pone.0230288.t002){ref-type="table"}).

10.1371/journal.pone.0230288.t002

###### Allelic profiles identified from the 103 fully typed samples in this study.

![](pone.0230288.t002){#pone.0230288.t002g}

  Sequence type                             Allelic profile                                23S rDNA (no. of samples)   Genetic group   Frequency
  ----------------------------------------- ---------------------------------------------- --------------------------- --------------- -----------
  1                                         1.3.1                                          R8(41)/X(2)                 SS14-like       43
  2                                         1.1.1                                          S(11)/R8(7)/R9(2)           SS14-like       20
  6                                         3.2.3                                          R(11)                       Nichols-like    11
  3                                         1.1.8                                          S(2)/R(2)                   SS14-like       4
  56[\*](#t002fn001){ref-type="table-fn"}   19[\*](#t002fn001){ref-type="table-fn"}.3.1    R8(4)                       SS14-like       4
  26                                        9.7.3                                          S(1)/R8(3)                  Nichols-like    4
  19                                        1.1.10                                         S(3)                        SS14-like       3
  28                                        1.17.9                                         R8(2)                       SS14-like       2
  57[\*](#t002fn001){ref-type="table-fn"}   1.43[\*](#t002fn001){ref-type="table-fn"}.1    R8(2)                       SS14-like       2
  58[\*](#t002fn001){ref-type="table-fn"}   1.44[\*](#t002fn001){ref-type="table-fn"}.1    R8(2)                       SS14-like       2
  60[\*](#t002fn001){ref-type="table-fn"}   9.2.3                                          S(2)                        Nichols-like    2
  61[\*](#t002fn001){ref-type="table-fn"}   1.3.3                                          R8(1)                       SS14-like       1
  62[\*](#t002fn001){ref-type="table-fn"}   1.32.10                                        S(1)                        SS14-like       1
  63[\*](#t002fn001){ref-type="table-fn"}   1.46[\*](#t002fn001){ref-type="table-fn"}.3    S(1)                        SS14-like       1
  64[\*](#t002fn001){ref-type="table-fn"}   1.47[\*](#t002fn001){ref-type="table-fn"}.1    R8(1)                       SS14-like       1
  65[\*](#t002fn001){ref-type="table-fn"}   20[\*](#t002fn001){ref-type="table-fn"}.2.10   S(1)                        Nichols-like    1
  59[\*](#t002fn001){ref-type="table-fn"}   7.45[\*](#t002fn001){ref-type="table-fn"}.9    R8(1)                       SS14-like       1

\*New sequence types and allelic variants were added to the BIGSdb database for *Treponema pallidum* subspecies *pallidum* \[[@pone.0230288.ref013]\].

All allelic profiles found in this study were visualized in a phylogenetic tree using the concatenated sequences ([Fig 3](#pone.0230288.g003){ref-type="fig"}). Their genetic diversity within the two major genetic clades, SS14 and Nichols, is clearly shown with 13 SS14-like allelic profiles and 4 Nichols-like allelic profiles.

![Phylogenic tree (unrooted) of the 17 allelic profiles.\
The Maximum Likelihood tree was constructed using the Timura-Nei method in MEGA6.06 with 1000 bootstraps.](pone.0230288.g003){#pone.0230288.g003}

There was a significant difference in the typability of ulcer swab samples from patients with primary syphilis, of which the isolates were more often fully typed, as compared to patients with secondary syphilis ([S1c Table](#pone.0230288.s001){ref-type="supplementary-material"}). In addition, secondary syphilis patients have a significantly higher RPR titer than primary patients (unpublished data) and all fully typed secondary syphilis isolates (n = 18) contained SS14-like TPA strains ([S2 Table](#pone.0230288.s002){ref-type="supplementary-material"}). No associations were found between the TPA types and ethnicity ([Fig 2](#pone.0230288.g002){ref-type="fig"}). Also, no significant differences were found based on the patient's HIV status, syphilitic stage or RPR titer of the typable isolates versus the non-typable isolates ([S1 Table](#pone.0230288.s001){ref-type="supplementary-material"}).

There were 123/137 (90%) isolates successfully sequenced for the relevant parts of the 23S rRNA genes and 81% of all isolates contained one of the macrolide resistance mutations, 79% contained the A2058G mutation and 2% the A2059G mutation. None of the isolates carried both mutations. Both of the samples containing the A2059G mutation had allelic profile 1.1.1. The prevalence of macrolide resistance causing mutations in the 23S rRNA genes showed an increased trend over time from 53% in 2007 to 79% in 2017 ([Fig 4](#pone.0230288.g004){ref-type="fig"}).

![Macrolide resistance causing mutations over time among the included isolates in Amsterdam between 2006 and 2018.](pone.0230288.g004){#pone.0230288.g004}

Discussion {#sec015}
==========

No TEN was found suggesting that bejel has not (yet) spread as a sexually transmitted disease to the Netherlands. By including Surinamese and Antillean patients who visited the Amsterdam STI clinic we aimed to increase the likelihood of finding strains from that geographical location which is close to Cuba where bejel was found within syphilis diagnosed patients \[[@pone.0230288.ref006]\]. An important limitation of this study is that we only had samples available from persons who reside in the Netherlands, probably all in the Amsterdam region. In addition, no data was available on the location of the acquisition of infection nor the ethnicity of the partners of these patients. Among these patients in Amsterdam with an Antillean or Surinamese ethnicity we did not see TEN infections, but it is still possible that bejel occurs in their countries of origin.

The most prevalent allelic profile found in this study was the SS14-like strain, 1.3.1 (42%), followed by 1.1.1 (19%) in concordance with similar TPA MLST studies \[[@pone.0230288.ref008], [@pone.0230288.ref012], [@pone.0230288.ref015], [@pone.0230288.ref016]\]. Until now, these two types have been found in every TPA MLST study \[[@pone.0230288.ref013]\], while all geographic locations (Czech Republic \[[@pone.0230288.ref016]\], Switzerland \[[@pone.0230288.ref008]\], France \[[@pone.0230288.ref012]\], Cuba \[[@pone.0230288.ref015]\], and the Netherlands) from which the samples were derived also have less common and unique allelic profiles suggesting the combination of global mixing populations and more local mixing of the hosts ([S3 Table](#pone.0230288.s003){ref-type="supplementary-material"}). To investigate possible bias in the typable versus not (fully) typable samples these groups were compared based on ethnicity, RPR titer, HIV status and syphilis stage. Of these variables, the syphilis stage of the patient showed a significant effect on the typability of the sample ([S1c Table](#pone.0230288.s001){ref-type="supplementary-material"}). Ulcer swab samples from patients with primary stage syphilis were significantly more likely to be fully typed than samples from secondary stage syphilis patients. A possible explanation may be that ulcers from primary syphilis patients contain more serous fluid as compared to the mostly dried and older ulcers present in secondary syphilis patients. Not surprisingly, patients with a secondary syphilis infection have a significant higher RPR titer than primary syphilis patients.

The use of the recently developed MLST for TPA strains allowed molecular characterization and subspecies determination with a high resolution for 103/137 (75%) of the selected samples. Obtaining a full type was more challenging for the older samples. Similar studies using this sequence based typing method obtained full types for up to 94% \[[@pone.0230288.ref015]\]. A previous molecular characterization study using the enhanced CDC method on isolates from Amsterdam showed a similar percentage of fully typed samples and a comparable typing distribution \[[@pone.0230288.ref017]\]. However, the enhanced CDC method combines partial sequence analysis of *tp0548* with the analysis of a restriction fragment length pattern of *tpr* genes and the number of acidic repeat proteins of 60bp each making it a complicated and occasionally unstable method \[[@pone.0230288.ref017]\] for TPA typing.

The genetic clade distribution found in this study were 83% SS14-like strains and 17% Nichols-like strains. This Nichols-like prevalence is more comparable to Argentina, Peru and Taiwan than to the countries closer to the Netherlands like France, Denmark, Ireland, the UK and the Czech Republic \[[@pone.0230288.ref018]\]. Worldwide only 117/1989 (5.9%) clinical samples were classified as Nichols-like \[[@pone.0230288.ref019]\]. This relatively high ratio of Nichols-like strains versus SS14-like strains was not explained by ethnicity as 2/16 (13%) fully typed samples from Antillean patients, 6/37 (16%) samples from Surinamese patients and 10/50 (20%) samples from Dutch patients, contained Nichols-like strains. Interestingly, all fully typed isolates from secondary stage syphilis patients contained TPA strains belonging to the SS14 clade ([S2 Table](#pone.0230288.s002){ref-type="supplementary-material"}), whereas an association was found between secondary stage syphilis and Nichols-like strains in a previous study \[[@pone.0230288.ref012]\].

Seven new allelic variants and 10 new ST were found adding to the knowledge of TPA strain diversity. All allelic variants and ST were added to the pubMLST BIGSdb database of TPA which was recently published for the surveillance and epidemiology of syphilis \[[@pone.0230288.ref013]\].

Furthermore, the successfully sequenced part of the 23S rRNA genes from 123/137 (90%) samples showed the presence of A2058G and A2059G mutations, 79% and 2% respectively. When analyzing the samples over time an increase in macrolide resistant mutations was seen from 53% in 2007 to 79% in 2017. The samples were not selected to investigate this as the distribution is not ideal, but the upward trend is significant and supports findings in earlier studies focusing on this topic \[[@pone.0230288.ref020]\].

The strain diversity found in this study reflects the local male STI clinic population which is a diverse, mixed group. Future studies should collect samples from the specific country of interest as ethnicity is not enough to investigate the epidemiology of bejel. Molecular characterization of the TPA bacteria remains important for network analyses and uncovering pathogenic associations with certain genetic variants.

Supporting information {#sec016}
======================

###### Fisher's Exact and Pearson Chi-squared tests for ethnicity, RPR titer, syphilis stage and HIV status versus typability of the samples.

S1a) Table. Pearson Chi-squared test for ethnicity and typability of samples. S1b) Table. Fisher's Exact test for RPR titer and typability of samples. S1c) Table. Pearson Chi-squared test for syphilis stage and typability of samples. S1d) Table. Fisher's Exact test for HIV status and typability of samples.

(DOCX)

###### 

Click here for additional data file.

###### Fisher's Exact test for syphilis stage versus genetic *Treponema pallidum* subspecies *pallidum* clade.

(DOCX)

###### 

Click here for additional data file.

###### Overview of full MLST *Treponema pallidum* subspecies *pallidum* types found in the public database \[[@pone.0230288.ref013]\].

(DOCX)

###### 

Click here for additional data file.
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We declare that all authors have seen and approved the manuscript, and have contributed significantly to the work. The manuscript presented here has not been published and is not being considered for publication elsewhere. None of the authors have declared a conflict of interest.

Finally, we did not receive any writing assistance other than copy-editing in the preparation of the manuscript.

We sincerely hope that you will consider our manuscript for publication in PLOS ONE.

On behalf of all co-authors,

Yours sincerely,

Hélène Zondag (corresponding author)

Public Health Laboratory,

Public Health Service of Amsterdam (GGD Amsterdam),

Nieuwe Achtergracht 100,

1018 WT Amsterdam,

the Netherlands

Phone: +31-20-5559205

E-mail: <hzondag@ggd.amsterdam.nl>

EDITOR'S COMMENTS

1\. We ask you to clarify under the method section how you defined primary and secondary syphilis.

Response: Thank you for your suggestion. We added the subsection "Defining clinical stages of syphilis" in the method section regarding the definition of the clinical syphilitic stages; "The primary stage of syphilis is defined as an oro-, ano-genital ulcerative disease with a positive dark field microscopy and/or with a positive ulcer swab PCR result. Criteria for secondary syphilis are a rash with or without lymphadenopathy, or mucosal lesions such as condylomata lata, and an RPR ≥ 1:4. Ulcers may also occur in patients presenting with a rash with or without lymphadenopathy, or mucosal lesions. These patients are diagnosed with secondary syphilis. All samples from this study are ulcer swabs and were derived from both (primary and secondary) clinical syphilis stages."

2\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming.

Response: All files (and filenames) have now been formatted to meet PLOS ONE's style requirements.

3\. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

Response: To increase transparency and to clarify our ethical clearing we added the requested details including the waived need for consent and the opt-out system regarding use of rest-materials from diagnostic samples (lines 153 -- 160). No minors were included. "This study was reviewed and the need for consent was waived by our Institutional Review Board, which is the Medical Ethical Committee of the Amsterdam University Medical Centers in the Netherlands. According to the Dutch Medical Research Act Involving Human Subjects on use of retrospective diagnostic material no additional ethical approval was required for this study (W19_113\#19.146). An opt-out system is used at the Public Health Service of Amsterdam to assure that if patients object to having their samples used for research that these are destroyed. Only anonymized patient data were used as provided by an independent datamanager. No samples from patients under the age of 18 years old were included."

REVIEWERS\' COMMENTS

Reviewer: 1

1\. In this manuscript by Zondag et al the possibility that TEN had reached the Nederlands is evaluated by typing Tp strains in patients with three different ethnicity attending STD clinics in the Netherlands.

Although the analysis of the samples obtained is technically sound and the results of the molecular analysis are clear and interesting, this reviewer does not particularity agree with the assumption that just looking at strains from patients with Antillean or Surinamese ethnicity is a adequate experimental design to address the question the authors pose.

Clearly the authors believe that these non-Dutch patients could have imported TEN case form their home countries, but in reality no data are provided to support that these infections were acquired elsewhere and not in the Nederlands. One should safely assume that these patients were not tourists, but no data are given about how long they lived in the Netherlands, ethnicity of their sexual partners and so on. So, in the context given, differentiating based on ethnicity seems rather nonscientific. Either the author revise their assumptions, or provide better justification for looking at such ethnic groups.

Response: Thank you for your critical reading and comments. We regret that our objectives were not stated clearly and have now made an attempt to clarify these aims better.

We were interested in discovering whether we could find bejel among our patients in the Amsterdam region who were diagnosed with syphilis. Lines 83-89 state our hypothesis for choosing the ethnicities in this study. We have rephrased this paragraph to more clearly describe and explain the study. "This study aimed to discover TEN strains causing bejel among syphilis cases from patients with Surinamese or Antillean ethnicity assuming possible importation of bejel from their country of origin. We hypothesized that if bejel was also misdiagnosed in Amsterdam, as was the case in Cuba among patients with syphilis \[6\], we would more likely find TEN in Dutch patients with a Surinamese or Antillean ethnicity, as these countries are geographically close to Cuba (Fig 1), than in patients with a Dutch ethnicity. Dutch patients were also included to investigate the presence of bejel in Amsterdam." We hypothesized that if bejel was misdiagnosed in Amsterdam, as was the case in Cuba among patients with syphilis (Noda et al, 2018) we maybe had a higher chance of detecting this phenomenon in patients whose roots were in countries closer to Cuba and who are Dutch citizens. Therefore we included patients from Surinam or the Antillean Islands since these countries are geographically close to Cuba.

Indeed, as the reviewer correctly assumes, these patients were not tourists, but actually Dutch citizens, which is what we stated in line 225 "we only had samples available from persons who reside in the Netherlands, probably all in the Amsterdam region".

Unfortunately no additional data is available on the location of the acquisition of the infection or on the ethnicity of the partners of these patients. To emphasize these limitations in the Discussion section we rephrased and expanded the following sentence (lines 224-229) "An important limitation of this study is that we only had samples available from persons who reside in the Netherlands, probably all in the Amsterdam region. In addition, no data was available on the location of the acquisition of infection nor on the ethnicity of the partners of these patients. Among these patients in Amsterdam with an Antillean or Surinamese ethnicity we did not see TEN infections, but it is still possible that bejel occurs in their countries of origin."

2\. Similarly, this reviewer believes that the authors\' conclusion that \"TEN has not (yet) reached the Netherlands does not have solid scientific basis, because it seems that 1) there are no data on TEN presence in Suriname or Antilles, and 2) with these samples, the authors might not have looked at all outside the local Dutch sexual network.

Response: We agree with the reviewer that it would indeed have been very interesting to also have samples from patients who live in Suriname and/or the Antilles, but we did not have these samples. See also our response to comment 1 why we still choose the samples as we did.

We also acknowledged the fact that these patients are residents from the Amsterdam region in line 225 "we only had samples available from persons who reside in the Netherlands, probably all in the Amsterdam region." With this in mind, stating the finding in our case like in line 53 (Abstract) "Bejel has thus not (yet) spread as a sexually transmitted disease in the Netherlands." and line 221 "No TEN was found suggesting that bejel has not (yet) spread as a sexually transmitted disease to the Netherlands." is a scientifically correct statement to make.

3\. More detail should be given about the kind of samples obtained for analysis from secondary syphilis patients.

Response: Thank you for your suggestion. We added a subsection under Methods named "Defining clinical stages of syphilis". By adding the following sentence (lines 119 -- 120) "All samples from this study are ulcer swabs and were derived from both (primary and secondary) clinical syphilis stages." we hope to have given more clarity on the type of samples used from secondary syphilis patients. Please also see our answer to the editor concerning the definition of primary and secondary syphilis cases.

Reviewer: 2

This is a well written paper and I have no major concerns. The finding is probably not that surprising and as the authors acknowledge it does not preclude bejel being transmitted in the countries of origin. I have no major comments requiring changes.

Response: Thank you for your positive response.
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